Market Research Logo

Digital Health Market: Focus on Digital Therapeutic, Monitoring and Diagnostic Solutions, 2018-2030

Digital Health Market: Focus on Digital Therapeutic, Monitoring and Diagnostic Solutions, 2018-2030

Chronic disorders, such as diabetes, heart disease, obesity, mental health problems and insomnia, are considered to be the leading causes of death and disability across the world. These are largely considered to be the consequence of unhealthy lifestyle choices and exposure to harmful disease stimulants. According to a 2018 report published by the Center for Managing Chronic Disease at the University of Michigan, more than 50% of the global population currently lives with some form of chronic disease. Projections indicate that the global prevalence of diabetes (considered to be one of the fastest-growing chronic disease indications), is around 451 million, and is expected to reach 693 million by 2025. In addition, the World Health Organization (WHO) estimates that, at present, 450 million people worldwide are suffering from some form of mental health problem and / or neurological disorder. The increasing prevalence of such clinical conditions has imposed a significant burden on the modern healthcare system. In the US, the cost burden related to such long term clinical conditions has been estimated to be approximately 86% of the USD 3.2 trillion that is spent by the country on healthcare, each year.

Digital healthcare, a relatively new concept that emerged only a few years ago, is believed to possess the potential to address the rising concerns related to the growing socio-economic burden. Driven by the demand for self-management approaches, personalized healthcare solutions and customized treatment regimens made available in the home-care setting, digital health companies are presently engaged in developing several innovative solutions for therapeutic, surveillance and diagnostic use. Various digital therapeutics, through behavioral and psychological interventions, have been designed to have a direct impact on the chronic clinical conditions by providing motivational support and encouraging patients to make better lifestyle choices. Such therapeutics are available in a variety of gaming solutions, standalone software applications or combinations of the aforementioned solutions with personal coaching support, artificial intelligence (AI) support and medical device(s). A number of digital therapeutics have already been marketed and a significant proportion of such candidate therapies are in R&D phase. In order to introduce such unconventional products into the market, companies have followed multiple approaches, which include both B2B and B2C variants. It is also worth highlighting that certain companies are even attempting to offer reimbursements for their proprietary products by conducting clinical trials in order to establish therapeutic credibility and convince insurance providers and payers.

Significant advancements have also been made towards the development of novel solutions for remote monitoring and diagnosis of chronic disorders. Such solutions have been developed to provide healthcare assistance in real-time through smartphone applications and connected devices. These solutions vary significantly in complexity and range from simple solutions capable of tracking weight loss, blood pressure, body temperature and heart rate to more sophisticated solutions systems that are equipped to independently conduct blood tests to confirm the presence of a bacterial / viral infection.

SCOPE OF THE REPORT
The ‘Digital Health Market: Focus on Digital Therapeutic, Monitoring & Diagnostic Solutions, 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for digital therapeutics, monitoring and diagnostic solutions that are either commercialized or under development within the healthcare industry. This burgeoning field presently offers a lot of opportunities to innovation focused start-ups and investors. Amongst other elements, the report features:

A discussion on the current market landscape of digital therapeutics, monitoring and diagnostic solutions, featuring information on the various developers of digital solutions, along with information on their type of solution offered, primary disease area, mechanism of action, purpose of solution, status of development (discovery, research / development, approved and marketed), launch year (if applicable) and business channels being used by stakeholders in this domain.

Detailed profiles of some of the emerging players in the industry, highlighting their current focus area(s), information on digital solutions offered and clinical research results (wherever available). Each profile also includes a section on recent developments and a comprehensive future outlook, highlighting the achievements, partnerships / collaborations, and the likely strategies that may be adopted by these players for future growth.

A comprehensive product competitiveness analysis of digital therapeutics for the most popular therapeutic areas taking into consideration the product portfolio (based on the total number of digital therapeutics being developed in that disease area) and key specifications of the solution, such as disease management support, user motivation features, tracking of health data and others.

A case study highlighting the focus area and results of clinical trials that have been conducted for the evaluation of various digital therapeutics.

An analysis of funding and investments made into companies involved in this segment of the overall healthcare industry; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants / awards received by these companies.

An analysis of the partnerships that have been forged between companies in this domain in the recent past, covering clinical trial collaborations, product development and commercialization agreements, pilot product offerings, product integration and other relevant agreements.

A detailed case study highlighting the various business models and go-to-market strategies adopted by companies involved in this space. It provides details on various channels being adopted by stakeholders in the industry to increase awareness and offer access to their proprietary products.

A SWOT analysis capturing the key parameters and trends that are likely to influence the future of digital therapeutics market.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on multiple parameters, such as prices of digital solutions, indication / region specific adoption trends, distribution channels and competitive landscape, we have provided an informed estimate on the likely evolution of digital therapeutics and digital monitoring / diagnostic solutions till 2030. We have segmented the market by therapeutic areas (such as metabolic disorders, mental health disorders, cardiovascular disorders, substance use disorders, neurological disorders, chronic pain disorders, sleep disorders and respiratory disorders), distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), purpose of solution (therapeutic or preventive), focus of solution (medication replacement or medication augmentation), type of solution (standalone software applications and software application + device or AI or personal coach) and key regions across the globe (North America (the US and Canada), Europe (Germany, France, Italy, the UK, Russia, and Spain), Asia-Pacific (China, Japan, India, Australia and South Korea) and rest of the world. In order to account for the uncertainties associated with the development of digital therapeutics and novel diagnostic / monitoring solutions and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Adam Kaufman (Canary Health), Amelie Janson (Voluntis), Prayat Shah (Co-founder, Vice President, Partnerships, Wellthy Therapeutics) and Reshma Nayak (Vice President, Marketing and Communications, Wellthy Therapeutics), Stephanie Tilenius (Vida Health) and Vijay Ravindran (Floreo). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS

1. There are over 100 digital therapeutics that are either commercially available (~27%) or are under development for the treatment of chronic disorders. Close to 30% of these solutions are focused on managing / treating metabolic disorders, such as diabetes. Examples include (in alphabetical order, no selection criteria) Betterise Diabetes (Betterise Health Tech), BlueStar (WellDoc), Diabeo (Voluntis), Lark Diabetes (Lark Health), NewMe Diabetes (Eco-Fusion) and Virta (Virta Health). These are followed by solutions (20%) that target mental health disorders. Other areas for which digital therapeutics are available / under evaluation include cardiovascular disorders, substance use disorders, neurological disorders, sleep disorders, respiratory disorders and chronic pain.

2. In terms of type of digital therapeutics, standalone software applications (share of ~40%) and software applications offered in combination with support of a personal health coach (share of ~14%) have emerged as the most popular types. Other types of digital therapeutics include gaming solutions (share of ~11%), packaged solutions featuring a software application, a device and support of a personal health coach (share of ~10%), and software applications featuring an artificial intelligence based assistant (share of ~7%).

3. Close to 60 digital solutions are also either commercially available or under development for remote digital monitoring and diagnosis of chronic clinical conditions. Of these, 17% are focused on monitoring of cardiovascular conditions, such as cardiac arrhythmias and heart failure. We observed that 13% and 12% of such products are intended for monitoring of patients suffering from metabolic disorders and infectious diseases, respectively. Other areas for which digital monitoring and diagnostic solutions have already been / are being developed include respiratory disorders, mental health conditions, oncological disorders, neurological disorders, ophthalmic disorders and substance use disorders.

4. Around 75% of the companies that are involved in the development of digital health solutions (which include therapeutic, monitoring and diagnostic solutions) for chronic disease management, are small-sized firms / start-ups (less than 50 employees). Examples of start-ups / small-sized companies that have developed / are developing digital therapeutics include (in alphabetical order, no selection criteria) Arthro Therapeutics, Better Therapeutics, BioTrak Therapeutics, Blue Mesa Health, Carrot Health, Dthera Sciences, Floreo, Kaia Health, Lief Therapeutics, Livongo Health, Pear Therapeutics, Vida Health, Virta Health, Vivid Vision and Wellthy Therapeutics. Similarly, examples of start-ups / small sized companies that are developing / have developed digital monitoring and diagnostic solutions include (in alphabetical order, no selection criteria) Athelas, Bioepic, Bodyport, BrainCheck, HealthReveal, iSono Health, Lifespot Health, LindaCare, Pixie Scientific, Rewire, Siren Care, Somatix, Spire and Voluntis.

5. Close to 200 partnerships have been inked between various stakeholders within the industry since 2008; of these, over 50 collaborations were signed in 2017 alone. Marketing & distribution and product integration agreements, with 15% share each, are the most popular partnership models. Examples of recently established deals include collaborations between Bioserenity and Pierre Fabre (May 2018), Big Health and Oxford AHSN (March 2018), Vheda Health and Prestige Health Choice (February 2018), WellDoc and Solera Health (January 2018), Omada Health and Cigna (October 2017), Glooko and Fit4D (April 2017), Voluntis and Sanofi (March 2017), and Qardio and Medelinked (February 2017).

6. Nearly USD 1 billion has been invested in companies operating in digital therapeutics segment over the last 10 years. Interestingly, close to half of the total amount (USD 478 million) was raised in 2017 and 2018, indicating that strategic investors have only recently realized the potential within this domain. Similarly, we identified close to 100 financing instances involving companies working in the monitoring and diagnostics segment of this market. The total amount invested in this sector was observed to be nearly USD 1.8 billion. Khosla Ventures, Social Capital, Merck Global Health Innovation Fund, Draper Fisher Jurveston, General Catalyst, Qualcomm Ventures, Rock Health, Social Capital and Canaan Partners emerged as some of the most active investors in this domain, based on the number of funding instances in which they participated.

7. In order to enhance the adoption of digital solutions in the market for chronic disease management, stakeholders in the industry are exploring innovative marketing strategies. One of the most common models used by companies is selling digital solutions through employer health plans. Other marketing strategies that are being implemented by companies include the use of social media platforms to spread awareness related to digital health solutions to appropriate target patient populations and increasing participation in global events, such as conferences, to gain the required visibility in the market.

8. The market for digital therapeutics is expected to grow at a CAGR of 19.7%% between 2018 and 2030. Similarly, for digital monitoring and diagnostic solutions, we expect the market to grow at an annualized rate of around 13.1% during the same period. Digital health solutions intended for the treatment / management of metabolic, cardiovascular and mental health disorders are expected to occupy majority of the share in the market during the forecast period.

9. North America (primarily the US) and Europe currently capture the largest share (close to 75%) of the overall digital health solutions market. This is followed by Asia-Pacific and rest of the world. As the industry matures, we expect Asia-Pacific to actively drive the growth owing to the sizable user base in the region, at a CAGR of 22.2% for digital therapeutics and 15.5% for digital monitoring & diagnostic solutions.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the digital therapeutics, monitoring and diagnostic solutions market in the mid to long term.

Chapter 3 provides a general overview of the digital health sector, covering details related to the current and future trends affiliated to the domain. The chapter highlights key concepts involved in the development of digital therapeutics. It also features a discussion on strategic initiatives undertaken by several organizations to support the development of digital solutions for treatment of chronic disorders. The chapter also provides an overview of the various product development pathways adopted by the companies in this field.

Chapter 4 includes information on over 100 digital therapeutics and close to 60 novel digital monitoring / diagnostic solutions that are currently being evaluated across different stages of development. The chapter features a comprehensive analysis of digital solutions, highlighting the target therapeutic areas, phases of development, type of solution, purpose of solution, and business models adopted for their marketing / sales. In addition, we have presented a comprehensive grid analysis of various digital solutions, highlighting their respective target therapeutic area, type of solution and phases of development. Further, the chapter features a dot-plot analysis of the most active players in the digital therapeutics sector, taking into consideration the status of development of various solutions and company’s current product portfolio specific to digital health.

Chapter 5 features detailed profiles of some of the emerging stakeholders that are offering digital therapeutics solutions for patients suffering from various types of chronic disorders. Each profile includes an overview of the company, details related to its digital solutions, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 6 includes detailed profiles of some of the emerging stakeholders that are offering digital solutions for monitoring or diagnosis of various types of chronic conditions. Each profile includes an overview of the company, details related to its digital solutions, recent developments and a comprehensive future outlook.
Chapter 7 presents a product competitiveness analysis of digital therapeutics on the basis of their respective target therapeutic areas. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 8 is a case study on the clinical trials that were / are being conducted for the evaluation of digital therapeutics. The chapter provides an overview of the specific objectives of the aforementioned studies of digital interventions intended for use by patients suffering from chronic disease indications. It features brief information on the study end-points as well.

Chapter 9 provides information on the funding instances and investments that have been made in both digital therapeutics and novel digital monitoring / diagnostics space. The chapter includes details on various investments (such as seed financing, venture funding, debt financing and grants) received by companies till May 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 10 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including pilot product offerings, product integration agreements, marketing and distribution agreements, product development agreements, product evaluation agreements, research and development agreements, acquisition agreements, product launch agreements, technology licensing agreements, product licensing agreements, clinical trial agreements and others ) and the most common forms of deals / agreements that have been established in the period between 2011 and 2018, in this field.

Chapter 11 features a detailed case study highlighting the go-to-market strategies adopted by companies engaged in this space. It presents insightful information on important marketing strategies, such as inbound marketing through social media platforms, promotional activities through official websites, business models and pricing models used by various players in the market.

Chapter 12 presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of digital solutions, indication / region specific adoption trends, distribution channels and competitive landscape. We have provided an informed estimate on the likely evolution of digital therapeutics and digital monitoring / diagnostic solutions. In addition, we have segmented the market by therapeutic areas (such as metabolic disorders, mental health disorders, cardiovascular disorders, substance use disorders, neurological disorders, chronic pain disorders, sleep disorders and respiratory disorders), distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), purpose of solution (therapeutic or preventive), focus of solution (medication replacement or medication augmentation), type of solution (standalone software applications and software application + device or AI or personal coach) and key regions across the globe (North America (the US and Canada), Europe (Germany, France, Italy, the UK, Russia, and Spain), Asia-Pacific (China, Japan, India, Australia and South Korea) and rest of the world.

Chapter 13 presents a detailed discussion on the future opportunities of digital solutions for chronic disease management. It also highlights the key parameters and trends that are likely to influence the future of this market, under a comprehensive SWOT framework.

Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Adam Kaufman (Canary Health), Amelie Janson (Voluntis), Prayat Shah (Co-founder, Vice President, Partnerships, Wellthy Therapeutics) and Reshma Nayak (Vice President, Marketing and Communications, Wellthy Therapeutics), Stephanie Tilenius (Vida Health) and Vijay Ravindran (Floreo).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.

1. 2Morrow
2. 3M Ventures
3. 500 Startups
4. 5AM Ventures
5. 7wire Ventures
6. Abbott
7. AbbVie
8. Aberdare Ventures
9. Academy of Managed Care Pharmacists
10. ACC
11. Accel Diagnostics
12. Accenture
13. Adage Capital Management
14. Adams Street Partners
15. Advanced Circulatory Systems
16. Advancit Capital
17. Aetna
18. Airbus
19. Akili Interactive
20. Akron Children's Hospital
21. Alexandria Venture Investments
22. AliveCor
23. Allen & Company
24. AltaMed
25. AME Cloud Partners
26. American Diabetes Association
27. American Investment Holdings
28. American Society of Mechanical Engineers
29. American Telemedicine Association
30. Amgen Venture
31. Andreessen Horowitz
32. Anorak Ventures
33. Anteo Diagnostics
34. Anyline
35. Aperture Venture Partners
36. Aplastic Anemia & MDS International Foundation
37. Apollo Hospitals
38. Apple
39. AppliedVR
40. Arboretum Ventures
41. Areta Health
42. Arthritis New Zealand
43. Arthro Therapeutics
44. Ascensia Diabetes Care
45. Ascension’s Brighton Center for Recovery
46. Aspect Ventures
47. Asthma and Allergy Foundation of America
48. AstraZeneca
49. AT&T
50. Athelas
51. Baillie Gifford
52. Beaumont Hospital
53. Becton Dickinson
54. Beehive Holdings
55. BEENEXT
56. BeHealth Solutions
57. Beneufit
58. Berger & Moore Advisors
59. Berklee's Institute for Creative Entrepreneurship
60. Bessemer Venture Partners
61. Better Therapeutics
62. Betterise Health Tech
63. Beurer
64. Big Health
65. Bigfoot Biomedical
66. Bigpoint
67. Bioepic
68. Biomark
69. BioSerenity
70. BioTrak Therapeutics
71. Biotricity
72. Bioventures Investors
73. Birla Institute of Technology and Science
74. bLife
75. Bloom Burton
76. Blue Mesa Health
77. Blue Spark Technologies
78. Blueprint Health
79. Bodyport
80. Boston Medical Center
81. Bpifrance Large Venture
82. BrainCheck
83. Breyer Capital
84. Bridge Builders Collaborative
85. Broadway Video Ventures
86. Brooklands Capital Strategies
87. Burrill & Company
88. Burston
89. C. Illies
90. Caffeinated Capital
91. California HealthCare Foundation
92. Cambia Health Solutions
93. Canaan Partners
94. Canary Foundation
95. Canary Health
96. Cancer Research Collaboration (CRC)
97. Canepa Advanced Healthcare Fund
98. Canvas Ventures
99. CapDecisif Management
100. Capricorn ICT Arkiv
101. CareFirst
102. Carrot Health
103. Castlight Health
104. Cavendish Global
105. CAVU Venture Partners
106. Cedars-Sinai Medical Center
107. Celebrate the Children
108. CellScope
109. Center for Autism Research (CAR)
110. Center for Managing Chronic Disease, University of Michigan
111. Center for the Advancement of Science in Space
112. Central Illinois Angels
113. Centria Healthcare Autism Services
114. Chicago Ventures
115. Children's Hospital of Philadelphia
116. Cigna
117. CIS Agriferts
118. Civilization Ventures
119. Claritas MindSciences
120. Click Therapeutics
121. CM-CIC Innovation
122. Colgate-Palmolive
123. COLOPL VR Fund
124. Columbia University Medical Center
125. Community College System of New Hampshire
126. Connecticut Innovations
127. CoreHealth Technologies
128. Correlation Ventures
129. COWEN
130. CPS Capital Group
131. CRCM Ventures
132. Creandum
133. Cue
134. Currae Healthtech
135. Cyrcadia Health
136. DAK-Gesundheit
137. Dartmouth College
138. Data Collective
139. Dataiku
140. DCM
141. Deerfield Management
142. Delivering Scientific Innovation for Autism
143. Dendera Ventures
144. Dentsu Ventures
145. Department of Veteran Affairs
146. Dermal Clinic
147. Dexcom
148. Diasend
149. Digitalis
150. Digithera
151. dLife
152. Draper Fisher Jurvetson
153. dRx Capital
154. Dthera Sciences
155. Echo Health Ventures
156. eClinical Works
157. Eco-Fusion
158. EDBI
159. Elevation Capital
160. Ellume
161. Emory University
162. Empatica
163. Empire Capital Partners
164. Endeavor Catalyst
165. Endotronix
166. Essex Woodlands
167. European School on Interdisciplinary Tinnitus Research
168. Eva Ventures
169. Excel Venture Management
170. Facebook
171. Felicis Ventures
172. FireStarter Fund
173. FirstMark Capital
174. Fit4D
175. FitBit
176. Flare Capital Partners
177. Flatiron Investors
178. Floodgate
179. Floreo
180. Florida Hospital
181. Flying Health
182. Force Over Mass Capital
183. Ford Motor Company
184. Forward Partners
185. Founder Collective
186. Founders Fund
187. Fred Hutchinson Cancer Research Center
188. Freelands Ventures
189. Fruit Street
190. Fuerst Technology Innovations
191. GAIA
192. GC VR Tracker Fund
193. GE Ventures
194. Genentech
195. General Catalyst
196. George Washington University School of Medicine
197. Georgian Partners
198. GlaxoSmithKline
199. Global to Local
200. Glooko
201. GluSense
202. GNS Healthcare
203. Greycroft
204. GrowX Venture Management
205. GSR Ventures
206. Hanmi IT
207. Harbor Pacific Capital
208. Harrison Metal
209. Health Care Originals
210. HealthReveal
211. HealthSlate
212. HealthTap
213. HealthX Ventures
214. Healthy Trucking Association of America
215. Heart Foundation
216. HelloFresh
217. Highmark Health
218. High-Tech Gründerfonds
219. Hikma Ventures
220. Hint
221. Hintsa Performance
222. Hospices Civils de Lyon
223. Hudson River Capital Partners
224. Human API
225. Humana
226. Hyde Park Angels
227. I2A Fund
228. iBionext
229. IBM
230. Idinvest Partners
231. IEEE
232. iHealth Lab
233. IIFL Select Equity Fund
234. i-Mercury Capital
235. Immortalana
236. iMotions
237. Impact First Investments
238. Incos Invest
239. Index Ventures
240. Initialized Capital
241. Innogest Capital
242. INNOTHERA
243. Innovate Health Tech NYC
244. Innovation Capital
245. Innovation Works
246. Innovationsstarter Fonds Hamburg
247. Institut de la Vision
248. Insulet
249. Intel Capital
250. Intermountain Healthcare
251. International Finance Corporation (IFC)
252. InterVest
253. Invitalia Ventures
254. iSeed Ventures
255. iSono Health
256. Israel Innovation Authority
257. Itochu
258. JamJar Investments
259. Janssen Research & Development
260. JAZZ Venture Partners
261. Jett Capital Advisors
262. John P. McGovern Museum of Health and Medical Science
263. Johns Hopkins School of Hygiene and Public Health
264. Johnson & Johnson Innovation
265. Joslin Diabetes Center
266. Joyable
267. Jumpstart Ventures
268. Juvenile Diabetes Research Foundation T1D fund
269. Kaia Health
270. Kaiser Permanente Ventures
271. Kapor Capital
272. Karuna Labs
273. Khosla Ventures
274. King's College London
275. Kinnevik
276. Kinsa
277. Kleiner Perkins Caufield & Byers
278. Kurbo Health
279. Kurma Diagnostics
280. Kyma Medical Technologies
281. Landmark Benefits
282. Lark Health
283. LB Investment
284. LBO France
285. Leman Micro Devices
286. LEO Innovation Lab
287. Lief Therapeutics
288. Life Sciences Discovery Fund
289. LifeForce Capital
290. Lifeforce Ventures
291. Lifeline Biotechnologies
292. Lifeline Ventures
293. LifeScan
294. Lifespot Health
295. LifeWatch
296. LifeWave Biomedical
297. Lightspeed Venture Partners
298. LindaCare
299. LinkedIn
300. Liquid 2 Ventures
301. Livongo Health
302. Louisiana Department of Health
303. Lumira Capital
304. Lund University
305. Lux Capital
306. M Ventures
307. M12
308. m8 Capital
309. Magellan Health
310. Manipal Education & Medical Group
311. MAP Health Management
312. Maryland Technology Development Corporation (TEDCO)
313. Massachusetts General Hospital
314. Max Healthcare
315. Mayfield Fund
316. Mayo Clinic
317. Medelinked
318. Medtronic
319. Melon Health
320. Merck
321. Meru Health
322. mHealth Technologies
323. Mid-Atlantic Telehealth Resource Center
324. Millar
325. Ministry of Health, Manatu Hauora
326. MIT Hacking Medicine
327. Mobio Technologies
328. Montage Ventures
329. Murray-Bertron
330. mySugr
331. Naluri Hidup
332. Nanobiosym Diagnostics
333. Nanon
334. NantHealth
335. National Aeronautics and Space Administration
336. National Cancer Institute
337. National Institute of Biomedical Imaging and Bioengineering
338. National Institute of Diabetes and Digestive and Kidney Diseases
339. National Institute of Mental Health and Neuro Sciences
340. National Institute on Drug Abuse (NIDA)
341. National Institutes of Health
342. National Multiple Sclerosis Society
343. Nemaura Medical
344. NeuroCure
345. NeuroMetrix
346. Neurotrack
347. New Enterprise Associates
348. New Mexico Retiree Health Care Authority (NMRHCA)
349. New World Ventures
350. Newtopia
351. Nexeon MedSystems
352. Nike
353. Nimbus Synergies
354. NODEHealth
355. Nokia Growth Partners
356. Noom
357. North Texas Angel Network
358. North York General Hospital
359. Northwell Ventures
360. Norwest Venture Partners
361. Norwich Ventures
362. Novant Health
363. Novartis
364. Novo Nordisk
365. Nueon
366. Nutrino
367. Obvious Ventures
368. Octopus Ventures
369. Oklahoma Life Science Fund
370. Omada Health
371. Omega Diagnostics
372. Omron Healthcare
373. Oncology Care Home Health
374. Onduo
375. Ontario Telemedicine Network
376. Open Medicine Institute
377. Oracle
378. OSF Ventures
379. Otsuka Pharmaceutical
380. Oxford Academic Health Science Network
381. Oxford Finance
382. Pallasite Ventures
383. Palo Alto Medical Foundation
384. Parasail Health
385. Partners in Health
386. PatientsLikeMe
387. Pear Therapeutics
388. Personal Health Solutions
389. Pfizer
390. Philips
391. Pierre Fabre
392. Pinterest
393. Pittsburgh Life Sciences Greenhouse
394. Pixie Scientific
395. Playground Global
396. PMV
397. Podimetrics
398. POPS! Diabetes Care
399. Premera Blue Cross
400. Presence Capital
401. Prestige Health Choice
402. Preventice Solutions
403. Pritzker Group Venture Capital
404. Profil Institute
405. Promus Ventures
406. Propeller Health
407. Proteus Digital Health
408. Provenance Venture Forum
409. Providence Health & Services
410. Purdue University
411. PureTech Health
412. Qardio
413. Qiming Venture Partners
414. Qualcomm Ventures
415. Quinze-Vingts National Ophthalmology Hospital
416. Quotas Beteiligungs
417. R7 Partners
418. RB Investments
419. Reaktor Ventures
420. Real Appeal
421. Recruit Strategic Partners
422. RedBrick Health
423. Redmile Group
424. Reflectance Medical
425. ResApp Health
426. Research Foundation for The State University of New York
427. Research Society for The Study of Diabetes in India (RSSDI)
428. Restore Health
429. Rethink Impact
430. Retina Foundation of the Southwest
431. Retrofit
432. Revon Systems
433. Rewire
434. Roche
435. Rock Health
436. R-Pharm
437. RRE Ventures
438. Rwandan Ministry of Health & National Reference Laboratory
439. Rx.Health
440. S.R. One
441. Safeguard Scientifics
442. Samsung
443. Sandoz
444. Sanitas
445. Sano Intelligence
446. Sanofi
447. Sapphire Ventures
448. Schoolhouse Partners
449. SciFi VC
450. Scrum Ventures
451. Selfridges
452. Sennheiser
453. Sequoia Capital
454. Servier
455. ShapeUp
456. Sherpa Capital
457. Shire
458. Signia Venture Partners
459. Silicon Valley Bank
460. Sino Portfolio International
461. Siren Care
462. Slow Ventures
463. Social Capital
464. Solera Health
465. Somatix
466. Sonormed
467. SOS Ventures
468. Sozo Ventures
469. Sparo
470. Spectrum Equity
471. Spire
472. SportsWareOnLine
473. Spotify
474. Spring Ridge Ventures
475. St. Joseph's Care Group
476. St. Jude Medical
477. St. Luke's Health System
478. St. Michael's Hospital
479. STADA
480. Stanford University
481. Stanley Park Ventures
482. Startup Funding Club
483. StartUp Health
484. Steelcase
485. Sunovion Pharmaceuticals
486. Sutter Health
487. SV Life Sciences
488. Sweet Capital
489. Swiss Re
490. Synovation Medical Group
491. Tactio Health Group
492. Teladoc
493. Telcare
494. Telefonica
495. Temasek Holdings
496. The Carlyle Group
497. The Chernin Group
498. The Robotics Hub
499. The Sync Project
500. The Valley Fund
501. The Venture Reality Fund
502. The Vertical Group
503. Thrive Capital
504. Tilak Healthcare
505. Tower Capital Partners
506. TransLink Capital
507. TreeHouse Health
508. TriplePoint Capital
509. True Ventures
510. True Wealth Ventures
511. Turnaround Health
512. Twine Health
513. Twitter
514. U.S. Venture Partners
515. uHealth Australia
516. Uncork Capital
517. UniQuest
518. United Healthcare
519. University Hospitals Leuven (UZ Leuven)
520. University Medical Center Goettingen
521. University of Bern
522. University of Calgary
523. University of California San Francisco
524. University of Hamburg
525. University of London
526. University of Lubeck
527. University of Maryland
528. University of Massachusetts Medical School
529. University of Michigan
530. University of Missouri
531. University of Nebraska
532. University of North Carolina
533. University of Oxford
534. University of Queensland
535. University of Rochester
536. University of Texas at Dallas
537. University of Texas Southwestern Medical School
538. University of Washington
539. UPMC Enterprises
540. Valeritas Holdings
541. Vanguard Medical Group
542. Venrock
543. Verily Life Sciences
544. Vertical Group
545. Vesalius Biocapital Partners
546. Vheda Health
547. Vida Health
548. Vimeo
549. Virgin Atlantic
550. Virta Health
551. VirtualScopics
552. Vital Art and Science
553. Vivid Vision
554. VNR Vignana Jyothi Institute of Engineering and Technology
555. Voluntis
556. Wake Forest University
557. Wanxiang America
558. Washington University School of Medicine
559. Welkin Health
560. WellDoc
561. Wellthy Therapeutics
562. Welltrinsic Sleep Network
563. West Coast Primary Health Organization
564. William Morris Endeavor
565. William Osler Health System
566. Windham Venture Partners
567. Withings
568. Workit Health
569. World Health Organization
570. XING
571. Xtreme Labs
572. Y Combinator
573. Yale University
574. YPSOMED
575. Zaffre Investments
576. Zoll Medical


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Digitization in Healthcare Sector
3.2. Next-Generation Healthcare Solutions
3.3. Key Concepts Associated with Digital Health Solutions
3.3.1. Cognitive Behavioral Therapy
3.3.2. Internet of Things
3.3.3. Big Data
3.3.4. Artificial Intelligence
3.3.5. Gamification
3.4. An Overview of Digital Therapeutics
3.4.1. Key Strategic Initiatives
3.4.1.1. Digital Therapeutics Alliance
3.4.1.2. Personal Connected Health Alliance
3.4.1.3. Programs Initiated by The Centers for Disease Control and Prevention
3.4.1.4. HIPAA Act
3.4.1.5. National Health Service Guidelines
3.4.1.6. USFDA Regulations for Digital Therapeutics
3.4.2. Typical Development and Commercialization Pathway for Digital Therapeutics
3.4.2.1. Discovery and Preclinical Phase
3.4.2.2. Clinical Trials and Validation
3.4.2.3. Negotiation with Insurance Providers / Payers
3.4.2.4. Distribution and Marketing
3.4.3. Rising Popularity of Digital Therapeutics
3.5. Remote Digital Monitoring and Diagnosis
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Distribution by Year of Establishment of Developer
4.2.2. Distribution by Geographical Location of Developer
4.2.3. Distribution by Size of Developer
4.2.4. Distribution by Type of Solution
4.2.5. Distribution by Primary Disease Area
4.2.6. Distribution by Therapeutic Area
4.2.7. Distribution by Purpose of Solution
4.2.8. Distribution by Focus of Solution
4.2.9. Distribution by Status of Development
4.2.10. Distribution of Type of Business Model
4.2.11 Grid Analysis
4.2.12. Dot Plot Analysis for Most Active Players
4.3. Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
4.3.1. Distribution by Year of Establishment of Developer
4.3.2. Distribution by Geographical Location of Developer
4.3.3. Distribution by Size of Developer
4.3.4. Distribution by Type of Solution
4.3.5. Distribution by Primary Disease Area
4.3.6. Distribution by Therapeutic Area
4.3.7. Distribution by Status of Development
4.3.8 Grid Analysis
5. DIGITAL THERAPEUTICS: COMPANY PROFILES
5.1. Chapter Overview
5.2. 2Morrow
5.2.1 Company Snapshot
5.2.2. Product Portfolio
5.2.3. Research Studies and Scientific Evidence
5.2.4. Recent Developments and Future Outlook
5.3. Akili Interactive
5.3.1. Company Snapshot
5.3.2. Product Portfolio
5.3.3. Research Studies and Scientific Evidence
5.3.4. Recent Developments and Future Outlook
5.4. Canary Health
5.4.1. Company Snapshot
5.4.2. Product Portfolio
5.4.3. Research Studies and Scientific Evidence
5.4.4. Recent Developments and Future Outlook
5.5 Floreo
5.5.1. Company Snapshot
5.5.2. Product Portfolio
5.5.3. Research Studies and Scientific Evidence
5.5.4. Recent Developments and Future Outlook
5.6. Omada Health
5.6.1. Company Snapshot
5.6.2. Product Portfolio
5.6.3. Research Studies and Scientific Evidence
5.6.4. Recent Developments and Future Outlook
5.7. Pear Therapeutics
5.7.1. Company Snapshot
5.7.2. Product Portfolio
5.7.3. Research Studies and Scientific Evidence
5.7.4. Recent Developments and Future Outlook
5.8. Vida Health
5.8.1. Company Snapshot
5.8.2. Product Portfolio
5.8.3 Research Studies and Scientific Evidence
5.8.4. Recent Developments and Future Outlook
5.9. WellDoc
5.9.1. Company Snapshot
5.9.2. Product Portfolio
5.9.3. Research Studies and Scientific Evidence
5.9.4. Recent Developments and Future Outlook
5.10. Wellthy Therapeutics
5.10.1. Company Snapshot
5.10.2. Product Portfolio
5.10.3. Research Studies and Scientific Evidence
5.10.4. Recent Developments and Future Outlook
6. DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
6.2. AliveCor
6.2.1. Company Snapshot
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. BioSerenity
6.3.1. Company Snapshot
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Cue
6.4.1. Company Snapshot
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Kinsa
6.5.1. Company Snapshot
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Voluntis
6.6.1. Company Snapshot
6.6.2. Product Portfolio
6.6.2.1. Digital Therapeutic Solutions
6.6.2.2. Digital Monitoring Solutions
6.6.3. Recent Developments and Future Outlook
7. KEY INSIGHTS: PRODUCT COMPETITIVENESS ANALYSIS AND MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Key Therapeutic Areas
7.2.1. Metabolic Disorders
7.2.1.1. Market Landscape
7.2.1.2. Product Competitiveness Analysis
7.2.2. Mental Health Problems
7.2.2.1. Market Landscape
7.2.2.2. Product Competitiveness Analysis
7.2.3. Neurological Disorders
7.2.3.1. Market Landscape
7.2.3.2. Product Competitiveness Analysis
7.2.4. Other Therapeutic Areas
8. DIGITAL THERAPEUTICS: CLINICAL RESEARCH EVIDENCE
8.1. Chapter Overview
8.2. Digital Therapeutics: Clinical Trials Data
8.3. Digital Therapeutics: Clinical Trials Data: Distribution by Therapeutic Areas
8.4. Digital Therapeutics: Clinical End-Points Analysis: Metabolic Disorders
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Digital Therapeutics: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Most Active Players in terms of Number of Instances
9.3.5. Most Active Players in terms of Amount of Funding
9.3.6. Most Active Investors in terms of Number of Instances
9.4. Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
9.4.1. Analysis by Number of Funding Instances
9.4.2. Analysis by Amount Invested
9.4.3. Analysis by Type of Funding
9.4.4. Most Active Players in terms of Number of Instances
9.4.5. Most Active Players in terms of Amount of Funding
9.4.6. Most Active Investors in terms of Number of Instances
10. COLLABORATIONS AND PARTNERSHIPS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Digital Therapeutics and Monitoring / Diagnostic Solutions: Recent Collaborations and Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Most Active Players
11. GO-TO-MARKET STRATEGY
11.1. Chapter Overview
11.2. Digital Therapeutic Developers: Marketing Strategies
11.2.1. Participation in Global Events
11.2.2. Marketing on Social Media Platforms
11.2.3. Marketing on Online / Print Media Platforms
11.2.4. Adoption of Different Business Models and Pricing Strategies
11.2.4.1. B2C Business Model
11.2.4.2. B2B Business Model
11.2.4.3. Pricing Strategy
11.2.5. Undertaking Various Promotional Activities
11.3. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2018-2030
12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2018-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2018-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2018-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2018-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2018-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2018-2030
12.4.7. Digital Therapeutics Market for Other Type of Solutions, 2018-2030
12.5. Global Digital Therapeutics Market: Distribution by Focus of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2018-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2018-2030
12.6. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.6.1 Digital Therapeutics Market for Therapeutic Solutions, 2018-2030
12.6.2. Digital Therapeutics Market for Preventive Solutions, 2018-2030
12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients), 2018-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030
12.8. Global Digital Therapeutics Market: Distribution by Geography
12.8.1 Digital Therapeutics Market in North America, 2018-2030
12.8.1.1 Digital Therapeutics Market in the US, 2018-2030
12.8.1.2 Digital Therapeutics Market in Canada, 2018-2030
12.8.2 Digital Therapeutics Market in Europe, 2018-2030
12.8.2.1. Digital Therapeutics Market in Germany, 2018-2030
12.8.2.2. Digital Therapeutics Market in France, 2018-2030
12.8.2.3. Digital Therapeutics Market in Russia, 2018-2030
12.8.2.4. Digital Therapeutics Market in Italy, 2018-2030
12.8.2.5. Digital Therapeutics Market in the UK, 2018-2030
12.8.2.6. Digital Therapeutics Market in Spain, 2018-2030
12.8.2.7. Digital Therapeutics Market in Rest of Europe, 2018-2030
12.8.3. Digital Therapeutics Market in Asia-Pacific, 2018-2030
12.8.3.1. Digital Therapeutics Market in China, 2018-2030
12.8.3.2. Digital Therapeutics Market in Japan, 2018-2030
12.8.3.3. Digital Therapeutics Market in India, 2018-2030
12.8.3.4. Digital Therapeutics Market in Australia, 2018-2030
12.8.3.5. Digital Therapeutics Market in South Korea, 2018-2030
12.8.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2018-2030
12.8.4. Digital Therapeutics Market in Rest of the World, 2018-2030
12.9. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.9.1. Digital Therapeutics Market for Metabolic Disorders, 2018-2030
12.9.1.1. Digital Therapeutics Market for Metabolic Disorders in North America, 2018-2030
12.9.1.2. Digital Therapeutics Market for Metabolic Disorders in Europe, 2018-2030
12.9.1.3. Digital Therapeutics Market for Metabolic Disorders in Asia-Pacific, 2018-2030
12.9.1.4. Digital Therapeutics Market for Metabolic Disorders in Rest of the World, 2018-2030
12.9.2. Digital Therapeutics Market for Mental Health Problems, 2018-2030
12.9.2.1. Digital Therapeutics Market for Mental Health Problems in North America, 2018-2030
12.9.2.2. Digital Therapeutics Market for Mental Health Problems in Europe, 2018-2030
12.9.2.3. Digital Therapeutics Market for Mental Health Problems in Asia-Pacific, 2018-2030
12.9.2.4. Digital Therapeutics Market for Mental Health Problems in Rest of the World, 2018-2030
12.9.3. Digital Therapeutics Market for Substance Use Disorders, 2018-2030
12.9.3.1. Digital Therapeutics Market for Substance Use Disorders in North America, 2018-2030
12.9.3.2. Digital Therapeutics Market for Substance Use Disorders in Europe, 2018-2030
12.9.3.3. Digital Therapeutics Market for Substance Use Disorders in Asia-Pacific, 2018-2030
12.9.3.4. Digital Therapeutics Market for Substance Use Disorders in Rest of the World, 2018-2030
12.9.4. Digital Therapeutics Market for Cardiovascular Disorders, 2018-2030
12.9.4.1. Digital Therapeutics Market for Cardiovascular Disorders in North America, 2018-2030
12.9.4.2. Digital Therapeutics Market for Cardiovascular Disorders in Europe, 2018-2030
12.9.4.3. Digital Therapeutics Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030
12.9.4.4. Digital Therapeutics Market for Cardiovascular Disorders in Rest of the World, 2018-2030
12.9.5. Digital Therapeutics Market for Chronic Pain, 2018-2030
12.9.5.1. Digital Therapeutics Market for Chronic Pain in North America, 2018-2030
12.9.5.2. Digital Therapeutics Market for Chronic Pain in Europe, 2018-2030
12.9.5.3. Digital Therapeutics Market for Chronic Pain in Asia-Pacific, 2018-2030
12.9.5.4. Digital Therapeutics Market for Chronic Pain in Rest of the World, 2018-2030
12.9.6. Digital Therapeutics Market for Sleep Disorders, 2018-2030
12.9.6.1. Digital Therapeutics Market for Sleep Disorders in North America, 2018-2030
12.9.6.2. Digital Therapeutics Market for Sleep Disorders in Europe, 2018-2030
12.9.6.3. Digital Therapeutics Market for Sleep Disorders in Asia-Pacific, 2018-2030
12.9.6.4. Digital Therapeutics Market for Sleep Disorders in Rest of the World, 2018-2030
12.9.7. Digital Therapeutics Market for Respiratory Disorders, 2018-2030
12.9.7.1. Digital Therapeutics Market for Respiratory Disorders in North America, 2018-2030
12.9.7.2. Digital Therapeutics Market for Respiratory Disorders in Europe, 2018-2030
12.9.7.3. Digital Therapeutics Market for Respiratory Disorders in Asia-Pacific, 2018-2030
12.9.7.4. Digital Therapeutics Market for Respiratory Disorders in Rest of the World, 2018-2030
12.9.8. Digital Therapeutics Market for Neurological Disorders, 2018-2030
12.9.8.1. Digital Therapeutics Market for Neurological Disorders in North America, 2018-2030
12.9.8.2. Digital Therapeutics Market for Neurological Disorders in Europe, 2018-2030
12.9.8.3. Digital Therapeutics Market for Neurological Disorders in Asia-Pacific, 2018-2030
12.9.8.4. Digital Therapeutics Market for Neurological Disorders in Rest of the World, 2018-2030
12.9.9. Digital Therapeutics Market for Other Disorders, 2018-2030
12.9.9.1. Digital Therapeutics Market for Other Disorders in North America, 2018-2030
12.9.9.2. Digital Therapeutics Market for Other Disorders in Europe, 2018-2030
12.9.9.3. Digital Therapeutics Market for Other Disorders in Asia-Pacific, 2018-2030
12.9.4.4. Digital Therapeutics Market for Other Disorders in Rest of the World, 2018-2030
12.10. Global Digital Monitoring / Diagnostic Solutions Market, 2018-2030
12.11. Global Digital Monitoring / Diagnostic Solutions Market: Distribution by Type of Solution
12.11.1. Digital Monitoring / Diagnostic Solutions Market for Standalone Software Applications, 2018-2030
12.11.2. Digital Monitoring / Diagnostic Solutions Market for Standalone Wearable Devices, 2018-2030
12.11.3. Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Device), 2018-2030
12.11.4. Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Wearable Device), 2018-2030
12.11.5. Digital Monitoring / Diagnostic Solutions Market for Other Type of Solutions, 2018-2030
12.12. Global Digital Monitoring / Diagnostic Solutions Market: Distribution by Business Model
12.12.1. Digital Monitoring / Diagnostic Solutions Market for B2C Model (Patients), 2018-2030
12.12.2. Digital Monitoring / Diagnostic Solutions Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030
12.13. Global Monitoring / Diagnostic Solutions Market: Distribution by Geography
12.13.1 Digital Monitoring / Diagnostic Solutions Market in North America, 2018-2030
12.13.1.1 Digital Monitoring / Diagnostic Solutions Market in the US, 2018-2030
12.13.1.2. Digital Monitoring / Diagnostic Solutions Market in Canada, 2018-2030
12.13.2 Digital Monitoring / Diagnostic Solutions Market in Europe, 2018-2030
12.13.2.1. Digital Monitoring / Diagnostic Solutions Market in Germany, 2018-2030
12.13.2.2. Digital Monitoring / Diagnostic Solutions Market in France, 2018-2030
12.13.2.3. Digital Monitoring / Diagnostic Solutions Market in Russia, 2018-2030
12.13.2.4. Digital Monitoring / Diagnostic Solutions Market in Italy, 2018-2030
12.13.2.5. Digital Monitoring / Diagnostic Solutions Market in the UK, 2018-2030
12.13.2.6. Digital Monitoring / Diagnostic Solutions Market in Spain, 2018-2030
12.13.2.7. Digital Monitoring / Diagnostic Solutions Market in Rest of Europe, 2018-2030
12.13.3. Digital Monitoring / Diagnostic Solutions Market in Asia-Pacific, 2018-2030
12.13.3.1. Digital Monitoring / Diagnostic Solutions Market in China, 2018-2030
12.13.3.2. Digital Monitoring / Diagnostic Solutions Market in Japan, 2018-2030
12.13.3.3. Digital Monitoring / Diagnostic Solutions Market in India, 2018-2030
12.13.3.4. Digital Monitoring / Diagnostic Solutions Market in South Korea, 2018-2030
12.13.3.5. Digital Monitoring / Diagnostic Solutions Market in Australia, 2018-2030
12.13.3.6. Digital Monitoring / Diagnostic Solutions Market in Rest of Asia-Pacific, 2018-2030
12.14. Global Monitoring / Diagnostic Solutions Market: Distribution by Therapeutic Area
12.14.1. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders, 2018-2030
12.14.1.1. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in North America, 2018-2030
12.14.1.2. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Europe, 2018-2030
12.14.1.3. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030
12.14.1.4. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Rest of the World, 2018-2030
12.14.2. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders, 2018-2030
12.14.2.1. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in North America, 2018-2030
12.14.2.2. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Europe, 2018-2030
12.14.2.3. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Asia-Pacific, 2018-2030
12.14.2.4. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Rest of the World, 2018-2030
12.14.3. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases, 2018-2030
12.14.3.1. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in North America, 2018-2030
12.14.3.2. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Europe, 2018-2030
12.14.3.3. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Asia-Pacific, 2018-2030
12.14.3.4. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Rest of the World, 2018-2030
12.14.4. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders, 2018-2030
12.14.4.1. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in North America, 2018-2030
12.14.4.2. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Europe, 2018-2030
12.14.4.3. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Asia-Pacific, 2018-2030
12.14.4.4. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Rest of the World, 2018-2030
12.14.5. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders, 2018-2030
12.14.5.1. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in North America, 2018-2030
12.14.5.2. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Europe, 2018-2030
12.14.5.3. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Asia-Pacific, 2018-2030
12.14.5.4. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Rest of the World, 2018-2030
12.14.6. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems, 2018-2030
12.14.6.1. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in North America, 2018-2030
12.14.6.2. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Europe, 2018-2030
12.14.6.3. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Asia-Pacific, 2018-2030
12.14.6.4. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Rest of the World, 2018-2030
12.14.7. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders, 2018-2030
12.14.7.1. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in North America, 2018-2030
12.14.7.2. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Europe, 2018-2030
12.14.7.3. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Asia-Pacific, 2018-2030
12.14.7.4. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Rest of the World, 2018-2030
12.14.8. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders, 2018-2030
12.14.8.1. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in North America, 2018-2030
12.14.8.2. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Europe, 2018-2030
12.14.8.3. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Asia-Pacific, 2018-2030
12.14.8.4. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Rest of the World, 2018-2030
12.14.9. Digital Monitoring / Diagnostic Solutions Market for Chronic Disorders, 2018-2030
12.14.9.1. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in North America, 2018-2030
12.14.9.2. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Europe, 2018-2030
12.14.9.3. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Asia-Pacific, 2018-2030
12.14.9.4. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Rest of the World, 2018-2030
13. FUTURE OF DIGITAL SOLUTIONS FOR CHRONIC DISEASE MANAGEMENT
13.1. Chapter Overview
13.2. Digital Health Solutions: SWOT Analysis
13.2.1. Strengths
13.2.2. Weaknesses
13.2.3. Opportunities
13.3.4. Threats
13.3. Digital Solutions for Chronic Disorders: Future Opportunities
13.3.1. Increasing Focus on Patient Centric Models
13.3.2. Applicability Across a Variety of Disease Indications
13.3.3. Increasing Emphasis on Real-World Evidence in R&D
13.3.4. Advances in IT and Computing Power to Foster Future Innovation
13.3.5. Rising Future Demand for Digital Solutions
13.4. Concluding Remarks
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Adam Kaufman, Chief Executive Officer, Canary Health
14.3. Amelie Janson, Communications Manager, Voluntis
14.4. Prayat Shah, Co-founder and Vice President, Partnerships, and Reshma Nayak Vice President, Marketing and Communications, Wellthy Therapeutics
14.5. Stephanie Tilenius, Co-Founder and Chief Executive Officer, Vida Health
14.6. Vijay Ravindran, Chief Executive Officer, Floreo
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Digital Health: Google Trends (2008-2018)
Figure 3.2 Internet of Things: Framework
Figure 3.3 Internet of Things: Applications in Healthcare
Figure 3.4 Prescription Digital Therapeutics: Process Map
Figure 3.5 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 3.6 Digital Therapeutics: Google Trends (2008-2018)
Figure 4.1 Digital Therapeutics: Distribution of Industry Players by Year of Establishment
Figure 4.2 Digital Therapeutics: Distribution of Industry Players by Geographical Location
Figure 4.3 Digital Therapeutics: Distribution of Industry Players by Size (Employee Count)
Figure 4.4 Digital Therapeutics: Distribution by Type of Solution
Figure 4.5 Digital Therapeutics: Distribution by Primary Disease Area
Figure 4.6 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.7 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.8 Digital Therapeutics: Distribution by Focus of Solution
Figure 4.9 Digital Therapeutics: Distribution by Status of Development
Figure 4.10 Digital Therapeutics: Distribution by Type of Business Model
Figure 4.11 Digital Therapeutics: Grid Analysis
Figure 4.12 Digital Therapeutics: Dot-Plot Analysis for Most Active Players
Figure 4.13 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Year of Establishment
Figure 4.14 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Geographical Location
Figure 4.15 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Size (Employee Count)
Figure 4.16 Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Figure 4.17 Digital Monitoring / Diagnostic Solutions: Distribution by Primary Disease Area
Figure 4.18 Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Figure 4.19 Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Figure 4.20 Digital Monitoring / Diagnostic Solutions: Grid Analysis
Figure 5.1 2Morrow Programs: Advantages
Figure 5.2 2Morrow: Product Portfolio and Treatment Approach
Figure 5.3 2Morrow Smoking Cessation Program: Top 10 Features Tracked by Participants in Clinical Study
Figure 5.4 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 5.5 Akili Interactive: Product Portfolio
Figure 5.6 Omada Health: Key Clinical Outcomes of Diabetes Prevention Program
Figure 5.7 Pear Therapeutics: Product Portfolio
Figure 5.8 Pear Therapeutics: Clinical Trial Results of reSET
Figure 5.9 WellDoc: Key Benefits of Diabetes Management Program
Figure 5.10 Wellthy Therapeutics: Diabetes Program
Figure 6.1 AliveCor: Benefits of Kardia
Figure 6.2 Cue: Key Elements of Digital Monitoring / Diagnostic Solution
Figure 6.3 Kinsa: Product Portfolio
Figure 7.1 Digital Therapeutics for Metabolic Disorders: Market Landscape
Figure 7.2 Digital Therapeutics for Mental Health Problems: Market Landscape
Figure 7.3 Digital Therapeutics for Neurological Disorders: Market Landscape
Figure 7.4 Digital Therapeutics for Other Therapeutic Areas: Market Landscape
Figure 8.1 Clinical Trials of Digital Therapeutics: Distribution by Therapeutic Areas
Figure 8.2 Clinical Trials of Digital Therapeutics: Primary Endpoints for Metabolic Disorders
Figure 9.1 Digital Therapeutics: Cumulative Number of Funding Instances, 2007-May-2018
Figure 9.2 Digital Therapeutics: Cumulative Amount Invested, 2007-May-2018 (USD Million)
Figure 9.3 Digital Therapeutics: Distribution of Funding Instances by Type, 2007- May-2018
Figure 9.4 Digital Therapeutics: Distribution of Total Amount Invested by Type of Funding, 2007-May-2018 (USD Million)
Figure 9.5 Digital Therapeutics: Most Active Players in terms of Number of Instances, 2007- May-2018
Figure 9.6 Digital Therapeutics: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Figure 9.7 Digital Therapeutics: Most Active Investors in terms of Number of Instances, 2007- May-2018
Figure 9.8 Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances, 2001- May-2018
Figure 9.9 Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested, 2001- May-2018 (USD Million)
Figure 9.10 Digital Monitoring / Diagnostic Solutions: Distribution of Funding Instances by Type, 2001-May-2018
Figure 9.11 Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding, 2001-May-2018 (USD Million)
Figure 9.12 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Instances, 2001- May-2018
Figure 9.13 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Figure 9.14 Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Instances
Figure 10.1 Recent Collaborations: Distribution by Year (2008– May 2018)
Figure 10.2 Recent Collaborations: Distribution by Type of Model
Figure 10.3 Recent Collaborations: Distribution by Type of Model and Year of Collaboration
Figure 10.4 Recent Collaborations: Distribution by Type of Model and Geographical Presence of Companies
Figure 10.5 Recent Collaborations: Most Active Companies
Figure 11.1 Go-to-Market Strategy: Active Commonly Used Social Media Platforms
Figure 11.2 Go-to-Market Strategy: Online / Print Media
Figure 11.3 Go-to-Market Strategy: Pricing Trends
Figure 11.4 Go-to-Market Strategy: Promotional Activities
Figure 12.1 Global Digital Therapeutics Market, 2018-2030 (USD Billion)
Figure 12.2 Digital Therapeutics Market for Standalone Software Applications, 2018-2030 (USD Billion)
Figure 12.3 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2018-2030 (USD Billion)
Figure 12.4 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2018-2030 (USD Billion)
Figure 12.5 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2018-2030 (USD Billion)
Figure 12.6 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2018-2030 (USD Billion)
Figure 12.7 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2018-2030 (USD Billion)
Figure 12.8 Digital Therapeutics Market for Other Type of Solutions, 2018-2030 (USD Billion)
Figure 12.9 Digital Therapeutics Market for Medication Replacement Solutions, 2018-2030 (USD Billion)
Figure 12.10 Digital Therapeutics Market for Medication Augmentation Solutions, 2018-2030 (USD Billion)
Figure 12.11 Digital Therapeutics Market for Therapeutic Solutions, 2018-2030 (USD Billion)
Figure 12.12 Digital Therapeutics Market for Preventive Solutions, 2018-2030 (USD Billion)
Figure 12.13 Digital Therapeutics Market for B2C Model (Patients), 2018-2030 (USD Billion)
Figure 12.14 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030 (USD Billion)
Figure 12.15 Digital Therapeutics Market in North America, 2018-2030 (USD Billion)
Figure 12.16 Digital Therapeutics Market in the US, 2018-2030 (USD Billion)
Figure 12.17 Digital Therapeutics Market in Canada, 2018-2030 (USD Billion)
Figure 12.18 Digital Therapeutics Market in Europe, 2018-2030 (USD Billion)
Figure 12.19 Digital Therapeutics Market in Germany, 2018-2030 (USD Billion)
Figure 12.20 Digital Therapeutics Market in France, 2018-2030 (USD Billion)
Figure 12.21 Digital Therapeutics Market in Russia, 2018-2030 (USD Billion)
Figure 12.22 Digital Therapeutics Market in Italy, 2018-2030 (USD Billion)
Figure 12.23 Digital Therapeutics Market in the UK, 2018-2030 (USD Billion)
Figure 12.24 Digital Therapeutics Market in Spain, 2018-2030 (USD Billion)
Figure 12.25 Digital Therapeutics Market in Rest of Europe, 2018-2030 (USD Billion)
Figure 12.26 Digital Therapeutics Market in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.27 Digital Therapeutics Market in China, 2018-2030 (USD Billion)
Figure 12.28 Digital Therapeutics Market in Japan, 2018-2030 (USD Billion)
Figure 12.29 Digital Therapeutics Market in India, 2018-2030 (USD Billion)
Figure 12.30 Digital Therapeutics Market in Australia, 2018-2030 (USD Billion)
Figure 12.31 Digital Therapeutics Market in South Korea, 2018-2030 (USD Billion)
Figure 12.32 Digital Therapeutics Market in Rest of Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.33 Digital Therapeutics Market in Rest of the World, 2018-2030 (USD Billion)
Figure 12.34 Digital Therapeutics Market for Metabolic Disorders, 2018-2030 (USD Billion)
Figure 12.35 Digital Therapeutics Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
Figure 12.36 Digital Therapeutics Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.37 Digital Therapeutics Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.38 Digital Therapeutics Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.39 Digital Therapeutics Market for Mental Health Problems, 2018-2030 (USD Billion)
Figure 12.40 Digital Therapeutics Market for Mental Health Problems in North America, 2018-2030 (USD Billion)
Figure 12.41 Digital Therapeutics Market for Mental Health Problems in Europe, 2018-2030 (USD Billion)
Figure 12.42 Digital Therapeutics Market for Mental Health Problems in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.43 Digital Therapeutics Market for Mental Health Problems in Rest of the World, 2018-2030 (USD Billion)
Figure 12.44 Digital Therapeutics Market for Substance Use Disorders, 2018-2030 (USD Billion)
Figure 12.45 Digital Therapeutics Market for Substance Use Disorders in North America, 2018-2030 (USD Billion)
Figure 12.46 Digital Therapeutics Market for Substance Use Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.47 Digital Therapeutics Market for Substance Use Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.48 Digital Therapeutics Market for Substance Use Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.49 Digital Therapeutics Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
Figure 12.50 Digital Therapeutics Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
Figure 12.51 Digital Therapeutics Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.52 Digital Therapeutics Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.53 Digital Therapeutics Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.54 Digital Therapeutics Market for Chronic Pain, 2018-2030 (USD Billion)
Figure 12.55 Digital Therapeutics Market for Chronic Pain in North America, 2018-2030 (USD Billion)
Figure 12.56 Digital Therapeutics Market for Chronic Pain in Europe, 2018-2030 (USD Billion)
Figure 12.57 Digital Therapeutics Market for Chronic Pain in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.58 Digital Therapeutics Market for Chronic Pain in Rest of the World, 2018-2030 (USD Billion)
Figure 12.59 Digital Therapeutics Market for Sleep Disorders, 2018-2030 (USD Billion)
Figure 12.60 Digital Therapeutics Market for Sleep Disorders in North America, 2018-2030 (USD Billion)
Figure 12.61 Digital Therapeutics Market for Sleep Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.62 Digital Therapeutics Market for Sleep Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.63 Digital Therapeutics Market for Sleep Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.64 Digital Therapeutics Market for Respiratory Disorders, 2018-2030 (USD Billion)
Figure 12.65 Digital Therapeutics Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
Figure 12.66 Digital Therapeutics Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.67 Digital Therapeutics Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.68 Digital Therapeutics Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.69 Digital Therapeutics Market for Neurological Disorders, 2018-2030 (USD Billion)
Figure 12.70 Digital Therapeutics Market for Neurological Disorders in North America, 2018-2030 (USD Billion)
Figure 12.71 Digital Therapeutics Market for Neurological Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.72 Digital Therapeutics Market for Neurological Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.73 Digital Therapeutics Market for Neurological Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.74 Digital Therapeutics Market for Other Disorders, 2018-2030 (USD Billion)
Figure 12.75 Digital Therapeutics Market for Other Disorders in North America, 2018-2030 (USD Billion)
Figure 12.76 Digital Therapeutics Market for Other Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.77 Digital Therapeutics Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.78 Digital Therapeutics Market for Other Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.79 Global Digital Monitoring / Diagnostic Solutions Market, 2018-2030 (USD Billion)
Figure 12.80 Digital Monitoring / Diagnostic Solutions Market for Standalone Software Applications, 2018-2030 (USD Billion)
Figure 12.81 Digital Monitoring / Diagnostic Solutions Market for Standalone Wearable Devices, 2018-2030 (USD Billion)
Figure 12.82 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Device), 2018-2030 (USD Billion)
Figure 12.83 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Wearable Device), 2018-2030 (USD Billion)
Figure 12.84 Digital Monitoring / Diagnostic Solutions Market for Other Type of Solutions, 2018-2030 (USD Billion)
Figure 12.85 Digital Monitoring / Diagnostic Solutions Market for B2C Model (Patients), 2018-2030 (USD Billion)
Figure 12.86 Digital Monitoring / Diagnostic Solutions Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030 (USD Billion)
Figure 12.87 Digital Monitoring / Diagnostic Solutions Market in North America, 2018-2030 (USD Billion)
Figure 12.88 Digital Monitoring / Diagnostic Solutions Market in the US, 2018-2030 (USD Billion)
Figure 12.89 Digital Monitoring / Diagnostic Solutions Market in Canada, 2018-2030 (USD Billion)
Figure 12.90 Digital Monitoring / Diagnostic Solutions Market in Europe, 2018-2030 (USD Billion)
Figure 12.91 Digital Monitoring / Diagnostic Solutions Market in Germany, 2018-2030 (USD Billion)
Figure 12.92 Digital Monitoring / Diagnostic Solutions Market in France, 2018-2030 (USD Billion)
Figure 12.93 Digital Monitoring / Diagnostic Solutions Market in Russia, 2018-2030 (USD Billion)
Figure 12.94 Digital Monitoring / Diagnostic Solutions Market in Italy, 2018-2030 (USD Billion)
Figure 12.95 Digital Monitoring / Diagnostic Solutions Market in the UK, 2018-2030 (USD Billion)
Figure 12.96 Digital Monitoring / Diagnostic Solutions Market in Spain, 2018-2030 (USD Billion)
Figure 12.97 Digital Monitoring / Diagnostic Solutions Market in Rest of Europe, 2018-2030 (USD Billion)
Figure 12.98 Digital Monitoring / Diagnostic Solutions Market in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.99 Digital Monitoring / Diagnostic Solutions Market in China, 2018-2030 (USD Billion)
Figure 12.100 Digital Monitoring / Diagnostic Solutions Market in Japan, 2018-2030 (USD Billion)
Figure 12.101 Digital Monitoring / Diagnostic Solutions Market in India, 2018-2030 (USD Billion)
Figure 12.102 Digital Monitoring / Diagnostic Solutions Market in South Korea, 2018-2030 (USD Billion)
Figure 12.103 Digital Monitoring / Diagnostic Solutions Market in Australia, 2018-2030 (USD Billion)
Figure 12.104 Digital Monitoring / Diagnostic Solutions Market in Rest of Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.105 Digital Monitoring / Diagnostic Solutions Market in Rest of the World, 2018-2030 (USD Billion)
Figure 12.106 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
Figure 12.107 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
Figure 12.108 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.109 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.110 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.111 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders, 2018-2030 (USD Billion)
Figure 12.112 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
Figure 12.113 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.114 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.115 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.116 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases, 2018-2030 (USD Billion)
Figure 12.117 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in North America, 2018-2030 (USD Billion)
Figure 12.118 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Europe, 2018-2030 (USD Billion)
Figure 12.119 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.120 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Rest of the World, 2018-2030 (USD Billion)
Figure 12.121 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders, 2018-2030 (USD Billion)
Figure 12.122 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
Figure 12.123 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.124 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.125 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.126 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders, 2018-2030 (USD Billion)
Figure 12.127 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in North America, 2018-2030 (USD Billion)
Figure 12.128 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.129 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.130 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.131 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems, 2018-2030 (USD Billion)
Figure 12.132 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in North America, 2018-2030 (USD Billion)
Figure 12.133 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Europe, 2018-2030 (USD Billion)
Figure 12.134 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.135 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Rest of the World, 2018-2030 (USD Billion)
Figure 12.136 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders, 2018-2030 (USD Billion)
Figure 12.137 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in North America, 2018-2030 (USD Billion)
Figure 12.138 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.139 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.140 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.141 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders, 2018-2030 (USD Billion)
Figure 12.142 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in North America, 2018-2030 (USD Billion)
Figure 12.143 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.144 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.145 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.146 Digital Monitoring / Diagnostic Solutions Market for Other Disorders, 2018-2030 (USD Billion)
Figure 12.147 Digital Monitoring / Diagnostic Solutions Market for Other Disorders in North America, 2018-2030 (USD Billion)
Figure 12.148 Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.149 Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.150 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Rest of the World, 2018-2030 (USD Billion)
LIST OF TABLES
Table 4.1 Digital Therapeutics: List of Solutions
Table 4.2 Digital Therapeutics: Overview of the Type of Solutions
Table 4.3 Digital Therapeutics: Information on Key Therapeutic Areas, Focus of Solution, Purpose of Solution and Stage of Development
Table 4.4 Digital Monitoring / Diagnostic Solutions: List of Solutions
Table 4.5 Digital Monitoring / Diagnostic Solutions: Overview of the Type of Solutions
Table 4.6 Digital Monitoring / Diagnostic Solutions: Information on Primary Disease Area, Therapeutic Area and Status of Development
Table 5.1 2Morrow: Key Highlights
Table 5.2 2Morrow: Recent Developments and Future Outlook
Table 5.3 Akili Interactive: Key Highlights
Table 5.4 Akili Interactive: Recent Developments and Future Outlook
Table 5.5 Canary Health: Key Highlights
Table 5.6 Canary Health: Recent Developments and Future Outlook
Table 5.7 Floreo: Key Highlights
Table 5.8 Floreo: Recent Developments and Future Outlook
Table 5.9 Omada Health: Key Highlights
Table 5.10 Omada Health: Recent Developments and Future Outlook
Table 5.11 Pear Therapeutics: Key Highlights
Table 5.12 Pear Therapeutics: Recent Developments and Future Outlook
Table 5.13 Vida Health: Key Highlights
Table 5.14 Vida Health: Recent Developments and Future Outlook
Table 5.15 WellDoc: Key Highlights
Table 5.16 WellDoc: Recent Developments and Future Outlook
Table 5.17 Wellthy Therapeutics: Key Highlights
Table 5.18 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 6.1 AliveCor: Key Highlights
Table 6.2 AliveCor: Recent Developments and Future Outlook
Table 6.3 BioSerenity: Key Highlights
Table 6.4 BioSerenity: Recent Developments and Future Outlook
Table 6.5 AliveCor: Key Highlights
Table 6.6 Kinsa: Key Highlights
Table 6.7 Kinsa: Recent Developments and Future Outlook
Table 6.8 Voluntis: Key Highlights
Table 6.9 Voluntis: Recent Developments and Future Outlook
Table 7.1 Digital Therapeutics for Metabolic Disorders: Product Competitiveness Analysis
Table 7.2 Digital Therapeutics for Mental Health Problems: Product Competitiveness Analysis
Table 7.3 Digital Therapeutics for Neurological Disorders: Product Competitiveness Analysis
Table 8.1 Digital Therapeutics: List of Clinical Trials (Details on Trial Title, NCT Number, Therapeutic Area, Sponsor, Collaborator and Trial Duration)
Table 8.2 Digital Therapeutics: List of Clinical Trials (Details on Primary Purpose, Primary and Secondary End- Points, Trial Location and Study Outcomes)
Table 9.1 Digital Therapeutics: Funding and Investments, 2007-2018
Table 9.2 Digital Therapeutics: Summary of Investments
Table 9.3 Digital Monitoring / Diagnostic Solutions: Funding and Investments, 2007- May-2018
Table 9.4 Digital Monitoring / Diagnostic Solutions: Summary of Investments
Table 10.1 Digital Therapeutics and Monitoring / Diagnostic Solutions: List of Partnerships
Table 11.1 Digital Therapeutics: Summary of Marketing Strategies
Table 11.2 Digital Therapeutics: Pricing Models
Table 12.1 Global Digital Therapeutics Market: Distribution Market: Distribution of Available / Under Development Solutions by Therapeutic Areas, % Share
Table 12.2 Global Digital Monitoring & Diagnostic Solutions Market: Distribution of Available / Under Development Solutions by Therapeutic Area, % Share
Table 12.3 Global Digital Therapeutics Market: Distribution of Available / Under Development Solutions by Type of Solutions, % Share
Table 12.4 Global Digital Monitoring & Diagnostic Solutions Market: Distribution of Available / Under Development Solutions by Type of Solutions, % Share
Table 12.5 Global Digital Therapeutics Market: Distribution of Available / Under Development Solutions by Purpose of Solution, % Share
Table 12.6 Global Digital Therapeutics Market: Distribution of Available / Under Development Solutions by Focus of Solution, % Share
Table 12.7 Global Digital Health Solutions Market: Distribution of Available / Under Development Solutions by Marketing Channel, % Share
Table 12.8 Global Digital Health Solutions Market: Distribution by Regions (2017, 2030), % Share
Table 15.1 Digital Therapeutics: Distribution of Industry Players by Year of Establishment
Table 15.2 Digital Therapeutics: Distribution of Industry Players by Geographical Location
Table 15.3 Digital Therapeutics: Distribution of Industry Players by Size (Employee Count)
Table 15.4 Digital Therapeutics: Distribution by Type of Solution
Table 15.5 Digital Therapeutics: Distribution by Primary Disease Area
Table 15.6 Digital Therapeutics: Distribution by Key Therapeutic Area
Table 15.7 Digital Therapeutics: Distribution by Purpose of Solution
Table 15.8 Digital Therapeutics: Distribution by Focus of Solution
Table 15.9 Digital Therapeutics: Distribution by Status of Development
Table 15.10 Digital Therapeutics: Distribution by Type of Business Model
Table 15.11 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Year of Establishment
Table 15.12 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Geographical Location
Table 15.13 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Size (Employee Count)
Table 15.14 Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Table 15.15 Digital Monitoring / Diagnostic Solutions: Distribution by Primary Disease Area
Table 15.16 Digital Monitoring / Diagnostic Solutions: Distribution by Key Therapeutic Area
Table 15.17 Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Table 15.18 Clinical Trials for Digital Therapeutics: Distribution by Therapeutic Areas
Table 15.19 Digital Therapeutics: Cumulative Number of Funding Instances, 2007 – May-2018
Table 15.20 Digital Therapeutics: Cumulative Amount Invested, 2007- May-2018 (USD Million)
Table 15.21 Digital Therapeutics: Distribution of Funding Instances by Type, 2007- May-2018
Table 15.22 Digital Therapeutics: Distribution of Total Amount Invested by Type of Funding, 2007- May-2018 (USD Million)
Table 15.23 Digital Therapeutics: Most Active Players in terms of Number of Instances, 2007- May-2018
Table 15.24 Digital Therapeutics: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Table 15.25 Digital Therapeutics: Most Active Investors in terms of Number of Instances, 2007- May-2018
Table 15.26 Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances, 2001- May-2018
Table 15.27 Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested, 2001- May-2018 (USD Million)
Table 15.28 Digital Monitoring / Diagnostic Solutions: Distribution of Funding Instance by Type, 2001- May-2018
Table 15.29 Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding, 2001- May-2018 (USD Million)
Table 15.30 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Instances, 2001- May-2018
Table 15.31 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Table 15.32 Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Instances
Table 15.33 Recent Collaborations: Distribution by Year (2008 – May 2018)
Table 15.34 Recent Collaborations: Distribution by Type of Model
Table 15.35 Recent Collaborations: Distribution by Type of Model and Year of Collaboration
Table 15.36 Recent Collaborations: Distribution by Type of Model and Geographical Presence of Companies
Table 15.37 Recent Collaborations: Most Active Companies
Table 15.38 Digital Therapeutics: Pricing Trend
Table 15.39 Global Digital Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.40 Digital Therapeutics Market for Standalone Software Applications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.41 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.42 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.43 Digital Therapeutics Market for Combination Offerings (Software Application + Device), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.44 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.45 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.46 Digital Therapeutics Market for Other Type of Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.47 Digital Therapeutics Market for Medication Replacement Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.48 Digital Therapeutics Market for Medication Augmentation Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.49 Digital Therapeutics Market for Therapeutic Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.50 Digital Therapeutics Market for Preventive Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.51 Digital Therapeutics Market for B2C Model (Patients), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.52 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.53 Digital Therapeutics Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.54 Digital Therapeutics Market in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.55 Digital Therapeutics Market in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.56 Digital Therapeutics Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.57 Digital Therapeutics Market in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.58 Digital Therapeutics Market in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.59 Digital Therapeutics Market in Russia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.60 Digital Therapeutics Market in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.61 Digital Therapeutics Market in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.62 Digital Therapeutics Market in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.63 Digital Therapeutics Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.64 Digital Therapeutics Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.65 Digital Therapeutics Market in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.66 Digital Therapeutics Market in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.67 Digital Therapeutics Market in India, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.68 Digital Therapeutics Market in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.69 Digital Therapeutics Market in South Korea, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.70 Digital Therapeutics Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.71 Digital Therapeutics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.72 Digital Therapeutics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.73 Digital Therapeutics Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.74 Digital Therapeutics Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.75 Digital Therapeutics Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.76 Digital Therapeutics Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.77 Digital Therapeutics Market for Mental Health Problems, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.78 Digital Therapeutics Market for Mental Health Problems in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.79 Digital Therapeutics Market for Mental Health Problems in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.80 Digital Therapeutics Market for Mental Health Problems in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.81 Digital Therapeutics Market for Mental Health Problems in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.82 Digital Therapeutics Market for Substance Use Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.83 Digital Therapeutics Market for Substance Use Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.84 Digital Therapeutics Market for Substance Use Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.85 Digital Therapeutics Market for Substance Use Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.86 Digital Therapeutics Market for Substance Use Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.87 Digital Therapeutics Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.88 Digital Therapeutics Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.89 Digital Therapeutics Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.90 Digital Therapeutics Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.91 Digital Therapeutics Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.92 Digital Therapeutics Market for Chronic Pain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.93 Digital Therapeutics Market for Chronic Pain in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.94 Digital Therapeutics Market for Chronic Pain in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.95 Digital Therapeutics Market for Chronic Pain in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.96 Digital Therapeutics Market for Chronic Pain in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.97 Digital Therapeutics Market for Sleep Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.98 Digital Therapeutics Market for Sleep Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.99 Digital Therapeutics Market for Sleep Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.100 Digital Therapeutics Market for Sleep Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.101 Digital Therapeutics Market for Sleep Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.102 Digital Therapeutics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.103 Digital Therapeutics Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.104 Digital Therapeutics Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.105 Digital Therapeutics Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.106 Digital Therapeutics Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.107 Digital Therapeutics Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.108 Digital Therapeutics Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.109 Digital Therapeutics Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.110 Digital Therapeutics Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.111 Digital Therapeutics Market for Neurological Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.112 Digital Therapeutics Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.113 Digital Therapeutics Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.114 Digital Therapeutics Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.115 Digital Therapeutics Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.116 Digital Therapeutics Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.117 Global Digital Monitoring / Diagnostic Solutions Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.118 Digital Monitoring / Diagnostic Solutions Market for Standalone Software Applications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.119 Digital Monitoring / Diagnostic Solutions Market for Standalone Wearable Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.120 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Device), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.121 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Wearable Device), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.122 Digital Monitoring / Diagnostic Solutions Market for Other Type of Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.123 Digital Monitoring / Diagnostic Solutions Market for B2C Model (Patients), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.124 Digital Monitoring / Diagnostic Solutions Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.125 Digital Monitoring / Diagnostic Solutions Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.126 Digital Monitoring / Diagnostic Solutions Market in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.127 Digital Monitoring / Diagnostic Solutions Market in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.128 Digital Monitoring / Diagnostic Solutions Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.129 Digital Monitoring / Diagnostic Solutions Market in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.130 Digital Monitoring / Diagnostic Solutions Market in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.131 Digital Monitoring / Diagnostic Solutions Market in Russia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.132 Digital Monitoring / Diagnostic Solutions Market in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.133 Digital Monitoring / Diagnostic Solutions Market in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.134 Digital Monitoring / Diagnostic Solutions Market in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.135 Digital Monitoring / Diagnostic Solutions Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.136 Digital Monitoring / Diagnostic Solutions Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.137 Digital Monitoring / Diagnostic Solutions Market in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.138 Digital Monitoring / Diagnostic Solutions Market in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.139 Digital Monitoring / Diagnostic Solutions Market in India, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.140 Digital Monitoring / Diagnostic Solutions Market in South Korea, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.141 Digital Monitoring / Diagnostic Solutions Market in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.142 Digital Monitoring / Diagnostic Solutions Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.143 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.144 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.145 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.146 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.147 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.148 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.149 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.150 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.151 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.152 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.153 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.154 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.155 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.156 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.157 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.158 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.159 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.160 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.161 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.162 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.163 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.164 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.165 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.166 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.167 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.168 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.169 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.170 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.171 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.172 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.173 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.174 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.175 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.176 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.177 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.178 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.179 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.180 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.181 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.182 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.183 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.184 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.185 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.186 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.187 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report